Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NEURONTIN vs KEPPRA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Gabapentin binds to the α2δ subunit of voltage-gated calcium channels, inhibiting calcium influx and reducing neurotransmitter release, particularly glutamate, norepinephrine, and substance P. It does not interact with GABA receptors.
Levetiracetam binds to synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability. It also inhibits high-voltage N-type calcium channels and reduces GABAergic and glycinergic inhibition.
Postherpetic neuralgia,Partial onset seizures (adjunctive therapy),Restless legs syndrome (off-label),Neuropathic pain (off-label),Diabetic peripheral neuropathy (off-label),Fibromyalgia (off-label),Generalized anxiety disorder (off-label)
Adjunctive therapy for partial-onset seizures (FDA),Adjunctive therapy for myoclonic seizures in juvenile myoclonic epilepsy (FDA),Adjunctive therapy for primary generalized tonic-clonic seizures (FDA),Off-label: Bipolar disorder, migraine prophylaxis, neuropathic pain, status epilepticus
300 mg orally once daily on day 1, 300 mg twice daily on day 2, then 300 mg three times daily on day 3; titrate up to effective dose, usual maintenance 300-600 mg three times daily, maximum 3600 mg/day.
500 mg orally twice daily, titrated up to 1500 mg twice daily as tolerated.
Terminal elimination half-life is 5–7 hours in patients with normal renal function; in elderly or those with renal impairment, half-life may be prolonged up to 132 hours; requires dose adjustment for creatinine clearance <60 m L/min.
6-8 hours in adults; prolonged to 10-18 hours in renal impairment (Cr Cl <30 m L/min); clinical context: dosing interval adjustment required in renal disease.
Gabapentin does not undergo hepatic metabolism; it is excreted unchanged in urine. No involvement of cytochrome P450 enzymes.
Levetiracetam is not extensively metabolized; ~66% of the dose is excreted unchanged in urine. Metabolism occurs via enzymatic hydrolysis of the acetamide group, independent of cytochrome P450. Major metabolite is the carboxylic acid derivative (ucb L057), which is pharmacologically inactive.
Renal elimination as unchanged drug: >90%; 0.3% is excreted in feces; biliary elimination is negligible.
Renal: 66% unchanged; 27% as inactive metabolite; 0.3% fecal.
<3% bound to plasma proteins (negligible).
<10% bound to plasma proteins (albumin).
Volume of distribution is 0.8 L/kg (57 L in a 70 kg adult), indicating distribution into total body water.
0.5-0.7 L/kg; approximates total body water; clinical meaning: extensive distribution into tissues, including brain.
Oral bioavailability is approximately 60% (30–90% with interindividual variability); decreases with higher doses due to saturable absorption; not affected by food.
Oral: 100% (immediate-release formulation); IV: 100%.
For Cr Cl 30-59 m L/min: 200-700 mg twice daily. For Cr Cl 15-29 m L/min: 200-700 mg once daily. For Cr Cl <15 m L/min: 100-300 mg once daily. Hemodialysis: loading dose 300-400 mg, then 200-300 mg after each 4-hour dialysis session.
Cr Cl 50-80 m L/min: 500-1000 mg every 12 hours; Cr Cl 30-49 m L/min: 250-750 mg every 12 hours; Cr Cl <30 m L/min: 250-500 mg every 12 hours; ESRD on dialysis: 500-1000 mg once daily with 250-500 mg supplemental dose after dialysis.
No specific dose adjustment guidelines; pharmacokinetics unchanged in hepatic impairment per manufacturer.
No specific adjustment for hepatic impairment; use caution in severe hepatic impairment.
For epilepsy (ages 3-12): initial 10-15 mg/kg/day in 3 divided doses, titrate over 3 days to effective dose, maintenance 25-35 mg/kg/day in 3 divided doses; maximum 50 mg/kg/day. For postherpetic neuralgia: not indicated.
1 month to <6 months: 7 mg/kg twice daily, titrate to 21 mg/kg twice daily; 6 months to <4 years: 10 mg/kg twice daily, titrate to 25 mg/kg twice daily; 4 to <16 years: 10 mg/kg twice daily, titrate to 30 mg/kg twice daily (maximum 3000 mg/day).
Initiate at lower dose (e.g., 100-300 mg/day) and titrate slowly; monitor for dizziness, sedation, and renal function; adjust dose based on creatinine clearance.
Start at 250-500 mg twice daily; titrate slowly due to age-related renal function decline.
None.
None
Respiratory depression: risk increased with opioid coadministration or in elderly patients,Central nervous system effects: dizziness, somnolence, ataxia,Increased seizure frequency with abrupt withdrawal,Suicidal behavior and ideation,Anaphylaxis and angioedema,Drug reaction with eosinophilia and systemic symptoms (DRESS),Pancreatitis,Abrupt discontinuation may precipitate status epilepticus in patients with seizures
Behavioral and psychiatric symptoms: psychosis, aggression, suicidal ideation,Somnolence and fatigue, dose-dependent,Stevens-Johnson syndrome and toxic epidermal necrolysis (rare),Hematologic abnormalities: decreased red blood cell, white blood cell, and platelet counts,Acute kidney injury (rare), intercurrent illness may increase risk,Avoid abrupt discontinuation to minimize seizure exacerbation or status epilepticus
Hypersensitivity to gabapentin or any component of the formulation
Hypersensitivity to levetiracetam or any of its components
No significant food interactions. Avoid alcohol due to additive CNS depression.
No significant food interactions. Levetiracetam absorption is not affected by food. Avoid alcohol as it may increase CNS depression.
First trimester: Increased risk of major congenital malformations (e.g., neural tube defects, heart defects) based on epidemiological data; avoid use if possible. Second and third trimester: Risk of fetal growth restriction, preterm birth, and neonatal withdrawal symptoms (e.g., feeding difficulties, irritability) after in utero exposure.
Increased risk of major congenital malformations, particularly neural tube defects (e.g., spina bifida), cleft palate, and cardiovascular defects, especially with first trimester exposure. Risk is dose-dependent and higher with polytherapy. Second and third trimester exposure may be associated with neurodevelopmental impairments.
Gabapentin is excreted into human milk; M/P ratio approximately 1.0. Limited data suggest low infant exposure (relative infant dose <2% of maternal weight-adjusted dose). Monitor infant for drowsiness, poor feeding, and gastrointestinal disturbances. Benefit of breastfeeding should be weighed against potential risks.
Levetiracetam is excreted into breast milk with an M/P ratio of approximately 1.0. Infant serum levels are about 10-30% of maternal levels. Generally considered compatible with breastfeeding, but monitor infant for drowsiness, poor feeding, and developmental milestones.
Increased clearance of gabapentin during pregnancy may require dose adjustments. Monitoring of clinical response and adverse effects is recommended. Consider gradual dose reduction postpartum to pre-pregnancy levels. No established dosing guidelines; individualize based on therapeutic response and tolerability.
Pregnancy increases levetiracetam clearance by 30-60%, especially in the second and third trimesters. Monitor serum trough concentrations every 1-2 months and increase dose as needed to maintain therapeutic levels. Postpartum, reduce dose to pre-pregnancy levels within the first week.
Titrate slowly to reduce CNS depression risk. Reduce dose in renal impairment (Cr Cl <60). Drug of choice for postherpetic neuralgia. Gabapentin is not effective for acute pain. Avoid abrupt discontinuation to prevent withdrawal. Use with caution with opioids due to respiratory depression risk.
Levetiracetam (Keppra) is a broad-spectrum AED with minimal drug interactions. Dosing must be adjusted for renal function (Cr Cl <80 m L/min). Monitor for behavioral changes, especially in pediatric patients. IV formulation can be administered without ECG monitoring. No need for therapeutic drug monitoring; efficacy and tolerability guide dosing.
May cause dizziness and drowsiness; avoid driving until effects known.,Take with or without food; avoid alcohol.,Do not stop suddenly; taper under doctor guidance.,May take time to work; adhere to prescribed dosing schedule.,Report any signs of allergic reaction, mood changes, or suicidal thoughts.
Take exactly as prescribed; do not stop suddenly as withdrawal seizures may occur.,Report any unusual mood changes, depression, or aggressive behavior to your doctor.,May cause dizziness or drowsiness; avoid driving until effects are known.,Take with or without food; do not crush extended-release tablets.,Drink plenty of fluids to prevent kidney stones, though not a common side effect.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NEURONTIN vs KEPPRA, answered by our medical review team.
NEURONTIN is a Antiepileptic that works by Gabapentin binds to the α2δ subunit of voltage-gated calcium channels, inhibiting calcium influx and reducing neurotransmitter release, particularly glutamate, norepinephrine, and substance P. It does not interact with GABA receptors.. KEPPRA is a Antiepileptic that works by Levetiracetam binds to synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability. It also inhibits high-voltage N-type calcium channels and reduces GABAergic and glycinergic inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NEURONTIN and KEPPRA depend on the specific clinical indication. These are both Antiepileptic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NEURONTIN is: 300 mg orally once daily on day 1, 300 mg twice daily on day 2, then 300 mg three times daily on day 3; titrate up to effective dose, usual maintenance 300-600 mg three times daily, maximum 3600 mg/day.. The standard adult dose of KEPPRA is: 500 mg orally twice daily, titrated up to 1500 mg twice daily as tolerated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NEURONTIN and KEPPRA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NEURONTIN is classified as Category C. First trimester: Increased risk of major congenital malformations (e.g., neural tube defects, heart defects) based on epidemiological data; avoid use if possible. Second and third . KEPPRA is classified as Category C. Increased risk of major congenital malformations, particularly neural tube defects (e.g., spina bifida), cleft palate, and cardiovascular defects, especially with first trimester e. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.